Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2021
This report can be delivered to the clients within 48 hours
DelveInsight’s, “Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2021,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
Chemotherapy Induced Peripheral Neuropathy: Overview
Chemotherapy-induced painful neuropathy (CIPN) is a predominantly sensory neuropathy that may be accompanied by motor and autonomic changes. CIPN is a major dose-limiting side effect of several first-line chemotherapeutic agents. The symptoms of CIPN include tingling, pain, decreased sensation, increased sensitivity to touch, temperature, pressure, pain; muscle weakness, and/or irreversible nerve damage. Diagnosis of CIPN is based on history, clinical examination and supporting laboratory investigations. These include electromyography with nerve conduction studies, skin biopsies to evaluate cutaneous nerve innervation, and nerve and muscle biopsies for histopathological evaluation. Treatment of CIPN depends on discontinuation or lowering the dose of the anti-cancer drug. Persistent neuropathic pain can be treated with anti-seizure medications, antidepressants, or analgesics including opiate drugs. Commonly used medications include Lyrica, Neurontin, Cymbalta, Celebrex, Elavil, and Lipoderm Patch. Regular exercise, occupational and physical therapy, reducing alcohol use, and treating preexisting medical conditions (vitamin B12 deficiency) may reduce the risk of CIPN.
'Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Peripheral Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Peripheral Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
This segment of the Chemotherapy Induced Peripheral Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chemotherapy Induced Peripheral Neuropathy Emerging Drugs
Further product details are provided in the report……..
Chemotherapy Induced Peripheral Neuropathy: Therapeutic Assessment
This segment of the report provides insights about the different Chemotherapy Induced Peripheral Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:
Chemotherapy Induced Peripheral Neuropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Peripheral Neuropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Peripheral Neuropathy drugs.
Chemotherapy Induced Peripheral Neuropathy Report Insights
Current Treatment Scenario and Emerging Therapies:
DelveInsight’s, “Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2021,” report provides comprehensive insights about 13+ companies and 13+ pipeline drugs in Chemotherapy Induced Peripheral Neuropathy pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
Geography Covered
- Global coverage
Chemotherapy Induced Peripheral Neuropathy: Overview
Chemotherapy-induced painful neuropathy (CIPN) is a predominantly sensory neuropathy that may be accompanied by motor and autonomic changes. CIPN is a major dose-limiting side effect of several first-line chemotherapeutic agents. The symptoms of CIPN include tingling, pain, decreased sensation, increased sensitivity to touch, temperature, pressure, pain; muscle weakness, and/or irreversible nerve damage. Diagnosis of CIPN is based on history, clinical examination and supporting laboratory investigations. These include electromyography with nerve conduction studies, skin biopsies to evaluate cutaneous nerve innervation, and nerve and muscle biopsies for histopathological evaluation. Treatment of CIPN depends on discontinuation or lowering the dose of the anti-cancer drug. Persistent neuropathic pain can be treated with anti-seizure medications, antidepressants, or analgesics including opiate drugs. Commonly used medications include Lyrica, Neurontin, Cymbalta, Celebrex, Elavil, and Lipoderm Patch. Regular exercise, occupational and physical therapy, reducing alcohol use, and treating preexisting medical conditions (vitamin B12 deficiency) may reduce the risk of CIPN.
'Chemotherapy Induced Peripheral Neuropathy - Pipeline Insight, 2021' report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Chemotherapy Induced Peripheral Neuropathy pipeline landscape is provided which includes the disease overview and Chemotherapy Induced Peripheral Neuropathy treatment guidelines. The assessment part of the report embraces, in depth Chemotherapy Induced Peripheral Neuropathy commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Chemotherapy Induced Peripheral Neuropathy collaborations, licensing, mergers and acquisition, funding, designations and other product related details.
Report Highlights
- The companies and academics are working to assess challenges and seek opportunities that could influence Chemotherapy Induced Peripheral Neuropathy R&D. The therapies under development are focused on novel approaches to treat/improve Chemotherapy Induced Peripheral Neuropathy.
This segment of the Chemotherapy Induced Peripheral Neuropathy report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.
Chemotherapy Induced Peripheral Neuropathy Emerging Drugs
- MN-166 (ibudilast): MediciNova
- ART-123: Asahi Kasei Pharma Corp.
Further product details are provided in the report……..
Chemotherapy Induced Peripheral Neuropathy: Therapeutic Assessment
This segment of the report provides insights about the different Chemotherapy Induced Peripheral Neuropathy drugs segregated based on following parameters that define the scope of the report, such as:
- Major Players in Chemotherapy Induced Peripheral Neuropathy
- Phases
- Late stage products (Phase III)
- Mid-stage products (Phase II)
- Early-stage product (Phase I) along with the details of
- Pre-clinical and Discovery stage candidates
- Discontinued & Inactive candidates
- Route of Administration
- Oral
- Parenteral
- Intravitreal
- Subretinal
- Topical
- Molecule Type
- Monoclonal Antibody
- Peptides
- Polymer
- Small molecule
- Gene therapy
- Product Type
Chemotherapy Induced Peripheral Neuropathy: Pipeline Development Activities
The report provides insights into different therapeutic candidates in phase III, II, I, preclinical and discovery stage. It also analyses Chemotherapy Induced Peripheral Neuropathy therapeutic drugs key players involved in developing key drugs.
Pipeline Development Activities
The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Chemotherapy Induced Peripheral Neuropathy drugs.
Chemotherapy Induced Peripheral Neuropathy Report Insights
- Chemotherapy Induced Peripheral Neuropathy Pipeline Analysis
- Therapeutic Assessment
- Unmet Needs
- Impact of Drugs
- Pipeline Product Profiles
- Therapeutic Assessment
- Pipeline Assessment
- Inactive drugs assessment
- Unmet Needs
Current Treatment Scenario and Emerging Therapies:
- How many companies are developing Chemotherapy Induced Peripheral Neuropathy drugs?
- How many Chemotherapy Induced Peripheral Neuropathy drugs are developed by each company?
- How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Chemotherapy Induced Peripheral Neuropathy?
- What are the key collaborations (Industry-Industry, Industry-Academia), Mergers and acquisitions, licensing activities related to the Chemotherapy Induced Peripheral Neuropathy therapeutics?
- What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
- What are the clinical studies going on for Chemotherapy Induced Peripheral Neuropathy and their status?
- What are the key designations that have been granted to the emerging drugs?
- MediciNova
- Asahi Kasei Pharma Corp.
- AnnJi Pharmaceutical
- EA Pharma
- Aptinyx
- Sonnet Biotherapeutics Holdings
- Toray
- Solasia Pharma
- Enveric Biosciences
- Regenacy Pharmaceuticals
- NeuroBo Pharmaceuticals
- MN-166
- ART-123
- AJ302
- EA-4017
- NYX-2925
- Recombinant Interleukin-6
- TRK-750
- SP-04
- Research programme: cannabidiol-combination therapies Enveric Biosciences
- Ricolinostat
- NB-01
Introduction
Executive Summary
Chemotherapy Induced Peripheral Neuropathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chemotherapy Induced Peripheral Neuropathy – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MN-166 (ibudilast): MediciNova
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EA-4017: EA Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Research programme: cannabidiol-combination therapies: Enveric Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chemotherapy Induced Peripheral Neuropathy Key Companies
Chemotherapy Induced Peripheral Neuropathy Key Products
Chemotherapy Induced Peripheral Neuropathy- Unmet Needs
Chemotherapy Induced Peripheral Neuropathy- Market Drivers and Barriers
Chemotherapy Induced Peripheral Neuropathy- Future Perspectives and Conclusion
Chemotherapy Induced Peripheral Neuropathy Analyst Views
Appendix
Executive Summary
Chemotherapy Induced Peripheral Neuropathy: Overview
Causes
Mechanism of Action
Signs and Symptoms
Diagnosis
Disease Management
Pipeline Therapeutics
Comparative Analysis
Therapeutic Assessment
Assessment by Product Type
Assessment by Stage and Product Type
Assessment by Route of Administration
Assessment by Stage and Route of Administration
Assessment by Molecule Type
Assessment by Stage and Molecule Type
Chemotherapy Induced Peripheral Neuropathy – DelveInsight’s Analytical Perspective
Late Stage Products (Phase III)
Comparative Analysis
Drug name: Company name
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Mid Stage Products (Phase II)
Comparative Analysis
MN-166 (ibudilast): MediciNova
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Early Stage Products (Phase I)
Comparative Analysis
EA-4017: EA Pharma
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Preclinical/Discovery Stage Products
Comparative Analysis
Research programme: cannabidiol-combination therapies: Enveric Biosciences
Product Description
Research and Development
Product Development Activities
Drug profiles in the detailed report…..
Inactive Products
Comparative Analysis
Chemotherapy Induced Peripheral Neuropathy Key Companies
Chemotherapy Induced Peripheral Neuropathy Key Products
Chemotherapy Induced Peripheral Neuropathy- Unmet Needs
Chemotherapy Induced Peripheral Neuropathy- Market Drivers and Barriers
Chemotherapy Induced Peripheral Neuropathy- Future Perspectives and Conclusion
Chemotherapy Induced Peripheral Neuropathy Analyst Views
Appendix
LIST OF TABLES
Table 1 Total Products for Chemotherapy Induced Peripheral Neuropathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
Table 1 Total Products for Chemotherapy Induced Peripheral Neuropathy
Table 2 Late Stage Products
Table 3 Mid Stage Products
Table 4 Early Stage Products
Table 5 Pre-clinical & Discovery Stage Products
Table 6 Assessment by Product Type
Table 7 Assessment by Stage and Product Type
Table 8 Assessment by Route of Administration
Table 9 Assessment by Stage and Route of Administration
Table 10 Assessment by Molecule Type
Table 11 Assessment by Stage and Molecule Type
Table 12 Inactive Products
LIST OF FIGURES
Figure 1 Total Products for Chemotherapy Induced Peripheral Neuropathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products
Figure 1 Total Products for Chemotherapy Induced Peripheral Neuropathy
Figure 2 Late Stage Products
Figure 3 Mid Stage Products
Figure 4 Early Stage Products
Figure 5 Preclinical and Discovery Stage Products
Figure 6 Assessment by Product Type
Figure 7 Assessment by Stage and Product Type
Figure 8 Assessment by Route of Administration
Figure 9 Assessment by Stage and Route of Administration
Figure 10 Assessment by Molecule Type
Figure 11 Assessment by Stage and Molecule Type
Figure 12 Inactive Products